Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's diabetes and weight-loss drug for up to $2 billion.Novo will pay The United Laboratories International $200 ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

We recently published a list of Was Jim Cramer Right About These 23 Stocks? In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...

Streamlined access to authentic, FDA-approved, rigorously-tested Zepbound comes from Sesame's direct integration with Gifthealth. Zepbound is the first and only FDA-approved dual glucagon-like peptide ...

Ben McPoland considers a pair of investments that are performing awfully in his ISA portfolio so far this year. What's gone ...

We recently published a list of 8 Best Robinhood Stocks to Buy According to Analysts. In this article, we are going to take a ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India, marking its entry into a rapidly growing market.

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

US pharma giant Eli Lilly has ventured into India with an anti-obesity and diabetes drug called Mounjaro. This development ...